Lv22
130 积分 2022-07-23 加入
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer
2小时前
已完结
Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer with Mutations Beyond EGFR 19del, L858R, and ALK rearrangement
2小时前
已完结
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
1天前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
2天前
已完结
Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer
6天前
已完结
Current perspective on resectability in stage III locally advanced NSCLC – the thoracic surgeons’ view
12天前
已关闭
Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double‐blind controlled trial
15天前
已完结
In the era of neoadjuvant chemoimmunotherapy, is there a role for radiation intensification therapy in patients with stage III (N2) non-small cell lung cancer (NSCLC) who undergo surgery? Results of LUN17-321 in the context of current clinical treatment options
18天前
已关闭
Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer
18天前
已完结
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
18天前
已完结
皖公网安备34019202002308
